Chaya Moskowitz, PhD

Attending Biostatistician

Chaya Moskowitz, PhD

Attending Biostatistician
Chaya Moskowitz, Attending  Biostatistician


University of Washington

Current Research Interests

Dr. Moskowitz’s primary collaborations are with investigators in the cancer survivorship and radiology research communities. She also provides statistical support to the MSK Exercise Oncology Service. She is involved in studies researching issues pertinent to survivors of cancer, particularly survivors of pediatric cancers. Much of this work has been focused on the epidemiological study of late effects of treatment for pediatric cancers, but she has also served as the lead statistician for randomized intervention studies in this population. She works with radiology investigators on the design and analysis of a variety of studies assessing different imaging modalities, potential imaging biomarkers, and different imaging-based response metrics in cancer clinical trials. Her primary research interest focuses on identifying and evaluating different methods and modalities for identifying childhood cancer survivors at high risk of breast cancer.


Selected peer-reviewed publications:

  1. Moskowitz CS, Pepe MS. Quantifying and comparing the accuracy of binary biomarkers when predicting a failure time outcome. Stat Med 2004; 23:1555-1570.
  2. Moskowitz CS, Pepe MS. Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs. Clinical Trials. 2006 June; 3:272-279.
  3. Moskowitz CS, Jia X, Schwartz LH, Gönen M. A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer. 2009 Jan; 45(2): 300-310.
  4. Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Friedman DN, Mubdi NZ, Leisenring WM, Stovall M, Hammond S, Smith SA, Henderson TO, Boice JD, Hudson MM, Diller LR, Bhatia S, Kenney LB, Neglia JP, Begg CB, Robison LL, Oeffinger KC. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014 Jul 20;32(21):2217-23.
  5. Moskowitz CS, Ronckers CM, Chou JF, Smith SA, Friedman DN, Barnea D, Kok JL, de Vries S, Wolden SL, Henderson TO, van der Pal HJH, Kremer LCM, Neglia JP, Turcotte LM, Howell RM, Arnold MA, Schaapveld M, Aleman B, Janus C, Versluys B, Leisenring W, Sklar CA, Begg CB, Pike MC, Armstrong GT, Robison LL, van Leeuwen FE, Oeffinger KC. Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts. J Clin Oncol. 2021 Sep 20;39(27):3012-3021. doi: 10.1200/JCO.20.02244. Epub 2021 May 28. PMID: 34048292.

Visit PubMed for a full listing of Chaya Moskowitz’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Chaya Moskowitz discloses the following relationships and financial interests:

  • Journal of the American Medical Association
    Professional Services and Activities
  • Radiological Society of North America
    Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures